Baricitinib for the Treatment of Cutaneous Dermatomyositis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study
J Am Acad Dermatol 2022 Aug 20;[EPub Ahead of Print], Q Zhao, Z Zhu, Q Fu, Y Shih, D Wu, L Chen, J Zheng, H CaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.